Target: CD2.
Clone: G11.
Specificity: Anti-CD2 In Vivo Antibody - Low Endotoxin (G11) recognizes Human CD2. Anti-Human CD2 recognizes a cell surface glycoprotein (Mr 45-59 kDa) on human lymphocytes.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: The CD2 antigen is present on approximately 80% of normal peripheral blood lymphocytes, >95% of thymocytes, 100% of mature circulating T-cells and a subset of NK cells.
Background: Appropriate pairs of anti-CD2 antibodies will stimulate peripheral T-cell proliferation and effector function. The CD2 molecule has been shown to be the receptor for leukocyte function antigen (LFA-3/CD58), the binding of which augments T-cell activation mediated by the T-cell antigen receptor (TCR). Anti-Human CD2 can be used to deplete CD2 positive cells by complement-mediated cytotoxicity. Analyses of NK lymphocyte subsets and identification of lymphomas and leukemias of T-cell origin have been done using Anti-CD2 antibodies.
Concentration: 1.0 - 5.0 mg/ml.
Formulation: 0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.
Purity: >95% by SDS-PAGE and HPLC.
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 5%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
